Marshall Wace, LLP X4 Pharmaceuticals, Inc Transaction History

Marshall Wace, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.03 - $2.02 $712,204 - $1.4 Million	-691,461 Reduced 98.17%	12,890 $14,000
Q2 2023 Aug 14, 2023	BUY	$0.82 - $2.49 $577,567 - $1.75 Million	704,351 New	704,351 $1.37 Million
Q2 2022 Aug 15, 2022	SELL	$0.88 - $1.91 $11,527 - $25,019	-13,099 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.48 - $2.58 $70,122 - $122,240	-47,380 Reduced 78.34%	13,099 $23,000
Q4 2021 Feb 14, 2022	BUY	$1.9 - $5.6 $66,986 - $197,433	35,256 Added 139.78%	60,479 $139,000
Q3 2021 Nov 15, 2021	BUY	$4.53 - $6.45 $52,158 - $74,265	11,514 Added 83.99%	25,223 $133,000
Q2 2021 Aug 13, 2021	BUY	$6.49 - $9.56 $88,971 - $131,058	13,709 New	13,709 $89,000

107

101M

418K

71.7K

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $45.3M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.